May 2, 2018 / 11:56 AM / 6 months ago

BRIEF-Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint

May 2 (Reuters) - Esperion Therapeutics Inc:

* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 LONG-TERM SAFETY STUDY OF BEMPEDOIC ACID

* ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY IN LARGEST AND LONGEST DURATION STUDY

* ESPERION - PATIENTS TREATED WITH BEMPEDOIC ACID ALSO ACHIEVED A SIGNIFICANT REDUCTION OF 22 PERCENT IN HIGH-SENSITIVITY C-REACTIVE PROTEIN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below